FiberSense plans CGM’s commercial readiness following CE mark

FiberSense’s device uses optical sensor technology to monitor the concentration of glucose in the subcutaneous tissue fluid. FiberSense’s device uses optical sensor technology to monitor the concentration of glucose in the subcutaneous tissue fluid. The European CGM market is dominated by Abbott. The company held a European market share of 76.8% in 2025, as per a GlobalData market model. Credit: SergeiShimanovich / Shutterstock.com FiberSense has obtained a CE mark for its continuous glucose monitoring (CGM) system, setting the stage for the medical device’s commercialisation in Europe. As with other CGMs, FiberSense’s system is designed for the continuous monitoring of blood…

Source: Medical Device Network